FST 344

FST-344 serves as a key endogenous antagonist of myostatin (GDF-8) and activin and is widely used in published research examining muscle hypertrophy, sarcopenia, muscular dystrophy models, and the broader activin/myostatin signalling pathways. Its main research role involves binding and neutralizing myostatin and activin, thereby inhibiting downstream signalling activity through TGF-β family receptor pathways. 

FST-344 is studied across multiple areas of scientific research, including:

• Muscle wasting and atrophy models, such as cachexia and sarcopenia, are used to evaluate the suppression of growth-inhibiting pathways.
• Muscle hypertrophy research focused on promoting lean mass through myostatin inhibition
• Regenerative medicine and tissue engineering applications involving tendon and ligament repair. 
• Metabolic research examining potential effects on lipid regulation and insulin sensitivity
• Broader signalling studies using FST-344 to better understand TGF-β superfamily regulatory networks.